2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Pleural Effusion, Malignant
4
Breast Neoplasms
4
Immunoglobulin Light-chain Amyloidosis
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Non-Hodgkin
2
Exanthema
2
Amyloidosis
2
Waldenstrom Macroglobulinemia
1
Urologic Neoplasms
1
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Tissue Adhesions
1
Skin Toxicity
1
Sezary Syndrome
1
Ras-wildtype Colorectal Cancer
1
Polyps
1
Polycystic Ovary Syndrome
1
Pleural Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Neurofibromatosis 2
1
Neoplasms, Second Primary
1
Neoplasms
1
Myoma
1
Menstruation Disturbances
1
Interventions
Paclitaxel
328
Carboplatin
323
Bevacizumab
171
Gemcitabine
106
liposomal doxorubicin
104
pembrolizumab
101
Cyclophosphamide
96
Topotecan
94
olaparib
92
Cisplatin
92
niraparib
69
Docetaxel
57
Taxes
52
Doxorubicin
51
Drug Therapy
45
fludarabine
40
Filgrastim
39
Nivolumab
37
Magnetic Resonance Spectroscopy
34
Surveys and Questionnaires
33
Specimen Handling
33
Etoposide
32
Hyperthermic Intraperitoneal Chemotherapy
31
Blood Specimen Collection
29
Immunoglobulin G
27
Disulfides
27
Peripheral Blood Stem Cell Transplantation
26
Cytoreduction Surgical Procedures
25
Albumin-Bound Paclitaxel
25
durvalumab
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Doxycycline
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn